Zhong Nanshan team recently said that in vitro studies have found that Baiyunshan Compound Radix Isatidis is effective against new coronavirus. Affected by the news, the stock prices of Baiyunshan (00874. HK) and Baiyunshan (600332. SH) rose sharply in the morning trading on October 16, and once touched the trading limit. As of the morning closing of the same day, Baiyunshan (600332. SH) rose 8.40% to 33.68 yuan / share, and Hong Kong stock Baiyunshan rose 12.76% to HK $21.65/share.
The news that Baiyunshan compound Banlangen Granules are effective against new coronavirus originated from the fourth council of "Guangdong Macao Joint Research Center for respiratory pathogens new drugs" on October 13.
According to public reports, after the signing ceremony, the scientific research achievements of Baiyunshan Banlangen and Baiyunshan compound Banlangen are planned to be industrialized in Macao, becoming the first landing project after the establishment of the Macao International Headquarters of Guangzhou Pharmaceutical Group. Zhong Nanshan will act as the chief scientist of the project and lead the team to carry out the rapid and efficient transformation of the research results of Isatis indigotica in Baiyun Mountain.
Academician Zhong Nanshan mentioned in the report. Since the outbreak of novel coronavirus, the research team has attached great importance to the research of the anti crown virus of South medicine. Combined with the beneficial experience of clinical practice, we have worked with Guangyao group to carry out in vitro screening of the new type of coronavirus in 16 Chinese patent medicines of 10 enterprises. We found that Fufang Banlangen Keli Baiyun Mountain had the inhibitory effect in vitro.
According to the semi annual report of 2020, during the reporting period, Baiyunshan achieved revenue of 30.47 billion yuan, a year-on-year decrease of 8.61%, and the net profit attributable to shareholders of listed companies was 1.764 billion yuan, a year-on-year decrease of 30.75%.
The decline of performance in the first half of the year was mainly due to the decrease in the number of patients in the hospital during the period of Xinguan epidemic, the limitation of logistics and distribution, and the decline of drug terminal demand. The sales volume of hospital sales varieties and related products in the Da Nan pharmaceutical plate decreased to varying degrees, and the pharmaceutical distribution business of the large commercial plate was also affected.
In addition, the market demand of Wanglaoji herbal tea was under pressure, the sales of Spring Festival stalls were greatly affected by the epidemic situation, and the decrease of government subsidies received by Wanglaoji health company on a year-on-year basis were also the reasons for the company's performance decline in the first half of the year.
On October 8, Baiyunshan announced that the company's board of directors had considered and approved the proposal to dismantle Guangzhou Pharmaceutical's initial public offering of H shares. In 2019 and the first half of 2020, the revenue of Guangzhou Pharmaceutical is 41.13 billion yuan and 19.662 billion yuan respectively, and the net profit is 340 million yuan and 171 million yuan, which is one of the important profit sources of Baiyunshan.